The Pneumonia Therapeutics Market is segmented into a wide variety of products for medical treatment of pneumonia, which is a dangerous lung infection resulting from bacterial, viral or fungal causes. This market also encompasses different therapeutic categories including antibiotics and antivirals, antifungal, and supportive care which seeks to reduce symptoms, enhance lung function, and avoid progression to complications. As the advancements in the healthcare system is made and people turning toward various investments in different respiratory diseases outcomes that pneumonia has on the global population, the market has shifted toward value-added products such as monoclonal antibodies and vaccines necessary to push forward additional improved results in treatment and decreasing the number of hospitalizations around the world. Pneumonia incidence persists and poses a threat to patients with other disorders such as children and the elderly, hence the increased need for adequate therapeutics.

Polyclonal Antibody Market Size Was Valued at USD 2.7 Billion in 2023, and is Projected to Reach USD 6.9 Billion by 2032, Growing at a CAGR of 4.9% From 2024-2032.